- Report
- January 2024
- 200 Pages
Global
From €4022EUR$4,150USD£3,445GBP
- Report
- October 2021
- 103 Pages
United States
From €2665EUR$2,750USD£2,283GBP
€5330EUR$5,500USD£4,565GBP
- Book
- April 2024
- 400 Pages
- Book
- June 2016
- 360 Pages
Tularemia is a rare, infectious disease caused by the bacterium Francisella tularensis. It is a potential bioterrorism agent due to its high infectivity and potential for aerosol transmission. The Tularemia market within the context of biodefense is focused on the development of vaccines, diagnostics, and therapeutics to protect against the disease. Vaccines are the primary focus of the market, as they are the most effective way to prevent infection. Diagnostics are also important, as they can be used to detect the presence of the disease in a timely manner. Therapeutics are also being developed to treat the disease, although they are not as effective as vaccines.
Companies in the Tularemia market include Emergent BioSolutions, DynPort Vaccine Company, and Bavarian Nordic. Show Less Read more